Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
A Phase I, Single-dose, Non-randomized, Open-label, Parallel Group Study to Assess the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
The purpose of this study is to measure the pharmacokinetics (PK), safety, and tolerability of capivasertib in participants with moderate hepatic impairment an…
Moderate Hepatic Impairment
AstraZenecaNCT07343960
Phase 1
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment
The primary purpose of this study is to evaluate the plasma PK of zanzalintinib following a single dose in participants with moderate liver dysfunction compare…
Hepatic ImpairmentModerate Hepatic Impairment
ExelixisNCT06962332